Douglas Thomson

EnteroBiotix Ltd. develops novel microbiome modulating drugs which are composed of live microorganisms. It focuses on faecal microbiota transplantation which transfers bacteria from a healthy donor into a recipient having an infection caused by a bacterium called C.difficile. The company was founded by James Roger McIlroy in March 2017 and is headquartered in Aberdeen, the United Kingdom.

EnteroBiotix Ltd. develops novel microbiome modulating drugs which are composed of live microorganisms. It focuses on faecal microbiota transplantation which transfers bacteria from a healthy donor into a recipient having an infection caused by a bacterium called C.difficile. The company was founded by James Roger McIlroy in March 2017 and is headquartered in Aberdeen, the United Kingdom.

EnteroBiotix Ltd. develops novel microbiome modulating drugs which are composed of live microorganisms. It focuses on faecal microbiota transplantation which transfers bacteria from a healthy donor into a recipient having an infection caused by a bacterium called C.difficile. The company was founded by James Roger McIlroy in March 2017 and is headquartered in Aberdeen, the United Kingdom.

EnteroBiotix Ltd. develops novel microbiome modulating drugs which are composed of live microorganisms. It focuses on faecal microbiota transplantation which transfers bacteria from a healthy donor into a recipient having an infection caused by a bacterium called C.difficile. The company was founded by James Roger McIlroy in March 2017 and is headquartered in Aberdeen, the United Kingdom.

EnteroBiotix Ltd. develops novel microbiome modulating drugs which are composed of live microorganisms. It focuses on faecal microbiota transplantation which transfers bacteria from a healthy donor into a recipient having an infection caused by a bacterium called C.difficile. The company was founded by James Roger McIlroy in March 2017 and is headquartered in Aberdeen, the United Kingdom.